Efficacy and Safety of Semaglutide Injection Vs WEGOVY in Chinese Obese Patients
Status:
RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.